---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-007404"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T02:35:08.223158+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Unicycive licenses Renazorb to Lotus for Korea; $0.75M upfront, up to $4.45M milestones

## Summary
- Exclusive license to Lotus for Renazorb in Republic of Korea; Lotus handles development, registration, importation, and commercialization costs.
- Unicycive receives $750,000 upfront and up to $4.45M in regulatory/commercial milestones plus tiered royalties.
- Renazorb is a phosphate binding agent for hyperphosphatemia in CKD patients; this is Unicycive's second Asian partnership.
- Lotus has nephrology presence in Korea via Alvogen Korea with 45% market share for Epoetin (IQVIA 3Q 2022).

## SEC filing metadata
- accession: 0001213900-23-007404
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/0001213900-23-007404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/ea172614-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-007404
- JSON: https://secwatch.observer/filing/0001213900-23-007404.json
- Plain text: https://secwatch.observer/filing/0001213900-23-007404.txt

## Key facts
- Material Agreements
  Unicycive Therapeutics, Inc. entered into License Agreement with Lotus International Pte Ltd. valued at $750,000 (effective 2023-02-01).
  - Action: entry
  - Agreement: license
  - Counterparty: Lotus International Pte Ltd.
  - Value: $750,000
  - Effective: 2023-02-01
  source text: Unicycive Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) effective as of February 1, 2023 with Lotus International Pte Ltd. (“Lotus”) pursuant to which the Company licensed the exclusive right to develop, market and commercialize Renazorb® to Lotus in the Republic of Korea. Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for Renazorb® in the licensed territory. In addition, Lotus will have sole responsibility for the importation of the drug product from Unicycive and for the costs of commercialization of Renazorb® in the licensed territory. The Company will receive an upfront payment of $750,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/0001213900-23-007404-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.